Amanote Research

Amanote Research

    RegisterSign In

Evidence for the Off-Label Use of Methylphenidate for Cognitive Enhancement in Healthy Individuals

Value in Health - United Kingdom
doi 10.1016/j.jval.2015.03.734
Full Text
Open PDF
Abstract

Available in full text

Categories
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
Date

May 1, 2015

Authors
G.V. Brito
Publisher

Elsevier BV


Related search

Methylphenidate Off-Label Use and Safety

SpringerPlus
Multidisciplinary
2014English

Off-Label Use of Clonidine for Sedation in Dutch ICUs

Critical Care
Critical CareIntensive Care Medicine
2014English

Medical Liability for Off Label Use of Drugs in Romania

Revista de Chimie
SurfacesMaterials ScienceEngineeringMaterials ChemistryFilmsCoatingsChemistry
2018English

Reasons for and Frequency of Off - Label Drug Use

Medicinski Pregled
Medicine
2015English

Available Evidence and Outcome of Off-Label Use of Rituximab in Clinical Practice

European Journal of Clinical Pharmacology
MedicinePharmacology
2013English

Off-Label Use of Bumetanide for Brain Disorders: An Overview

Frontiers in Neuroscience
Neuroscience
2019English

«Off Label Use»: Nouvelles Recommandations

Bulletin des Médecins Suisses
2007English

Off-Label Use of Approved Drugs

Nature Reviews Clinical Oncology
Oncology
2009English

Off-Label Use of Bevacizumab for Wet Age-Related Macular Degeneration in Europe

Graefe's Archive for Clinical and Experimental Ophthalmology
Molecular NeuroscienceOphthalmologySensory SystemsCellular
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy